Cwm LLC Trims Stake in Eli Lilly and Company $LLY

Cwm LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 10.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,743 shares of the company’s stock after selling 10,890 shares during the quarter. Cwm LLC’s holdings in Eli Lilly and Company were worth $69,177,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hobbs Wealth Management LLC boosted its position in Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC boosted its position in Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC boosted its position in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after acquiring an additional 12 shares during the last quarter. Ascent Capital Management LLC boosted its position in Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after acquiring an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners boosted its position in Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock worth $407,000 after acquiring an additional 13 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have weighed in on LLY. Leerink Partners reiterated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. HSBC boosted their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Berenberg Bank reiterated a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $948.06.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $833.08 on Monday. The firm’s 50 day moving average price is $742.42 and its 200-day moving average price is $765.55. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The firm has a market cap of $788.47 billion, a P/E ratio of 54.45, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.